Profile data is unavailable for this security.
About the company
Biophytis SA, formerly Institut Biophytis Sas is a France-based company engaged in the healthcare industry. The Company is a biotechnology entity specialized in the development of drug candidates to treat ageing diseases. Its two programs relate to sarcopenia (loss of muscle functionality) and Age Related Macular Degeneration (ARMD). Biophytis SA is engaged in the clinical and regulatory development of its drug candidates, such as Sarconeos (BIO101) and Macuneos (BIO201), simultaneously in the United States and domestic market.
- Revenue in EUR (TTM)0.00
- Net income in EUR-15.07m
- Incorporated2006
- Employees22.00
- LocationBiophytis SA14 avenue de l'OperaPARIS 75001FranceFRA
- Phone+33 141836600
- Websitehttps://www.biophytis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Theravet SA | -100.00bn | -100.00bn | 353.63k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Biophytis SA | 0.00 | -15.07m | 1.36m | 22.00 | -- | -- | -- | -- | -6.54 | -6.54 | 0.00 | -1.22 | 0.00 | -- | -- | 0.00 | -129.28 | -97.52 | -- | -487.25 | -- | -- | -- | -- | -- | -5.75 | 5.28 | -- | -- | -- | 29.69 | -- | 14.25 | -- |
Medesis Pharma SA | 0.00 | -3.96m | 1.90m | 10.00 | -- | -- | -- | -- | -0.7916 | -0.7916 | 0.00 | -0.9071 | 0.00 | 0.3139 | -- | -- | -206.12 | -126.10 | -- | -300.50 | -- | 70.78 | -- | -2,552.19 | 0.467 | -26.37 | -- | -- | -- | -- | -44.04 | -- | -- | -- |
GeNeuro SA | 0.00 | -14.76m | 2.37m | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
IntegraGen SA | 12.54m | -171.40k | 3.32m | 55.00 | -- | 1.62 | 123.96 | 0.2651 | -0.025 | -0.025 | 1.90 | 0.3041 | 1.47 | 12.06 | 4.06 | 227,953.30 | -2.01 | -1.93 | -4.78 | -4.41 | 66.41 | 65.11 | -1.37 | -1.51 | 1.57 | -- | 0.3587 | -- | -4.78 | 12.61 | -4,783.19 | -- | -- | -- |
Theranexus SA | 0.00 | -3.08m | 3.84m | 12.00 | -- | -- | -- | -- | -0.3971 | -0.3971 | 0.00 | -0.0004 | 0.00 | -- | -- | 0.00 | -50.35 | -42.66 | -64.95 | -47.97 | -- | -- | -- | -- | -- | -420.89 | 1.00 | -- | -- | -- | -3.97 | -- | -33.23 | -- |
Quantum Genomics SA | 10.06k | -3.17m | 5.89m | 3.00 | -- | 6.74 | -- | 585.54 | -0.091 | -0.091 | 0.0003 | 0.0125 | 0.0007 | -- | 0.0016 | 3,353.33 | -23.14 | -60.77 | -95.19 | -102.24 | -14,205.07 | -3,548.91 | -31,520.38 | -3,374.13 | -- | -146.53 | 0.8615 | -- | -98.34 | -- | 87.28 | -- | -- | -- |
Data as of Oct 09 2024. Currency figures normalised to Biophytis SA's reporting currency: Euro EUR
Holder | Shares | % Held |
---|---|---|
Gestys SAas of 23 Feb 2024 | 55.95k | 1.07% |
Data from 28 Jun 2024 - 28 Jun 2024Source: FactSet Research Systems Inc.